You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康希諾生物八連漲破頂 聯手天津市藥監局共建國內首個疫苗實訓基地
格隆匯 11-27 14:45
格隆匯11月27日丨康希諾生物(6185.HK)漲4.65%,有望實現連續第八個交易日上漲,報52.85港元,刷新其上市以來新高,成交3127萬港元,總市值117.67億港元。天津藥監局和康希諾生物昨日簽署“協同發展合作備忘錄”,作為雙方合作的重要組成部分,由天津市藥監局和康希諾生物合作共建的國內首個疫苗實訓基地也於當日正式揭牌成立。此外,康希諾生物股份公司首次公開發行股票並在科創板上市已經接受輔導,或將成為又一家H股+A科創板上市公司。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account